CYTKHIGH SIGNALFINANCIAL10-K

CYTK shows severe financial deterioration with revenue collapsing 87% while losses deepened significantly and stockholders' equity plunged into deeply negative territory.

The dramatic revenue decline from $106M to $13M suggests loss of a major revenue source or clinical setback, while the company continues burning substantial cash with operating losses exceeding $510M. The stockholders' equity deteriorating to negative $660M indicates the company's liabilities now far exceed assets, creating potential going concern issues.

Comparing 2026-02-26 vs 2025-02-27View on EDGAR →
FINANCIAL ANALYSIS

CYTK experienced a financial crisis with revenue collapsing 87% to just $13.4M while operating cash burn worsened to -$510M and net losses deepened to -$785M. The balance sheet deteriorated severely with stockholders' equity plummeting to negative $660M as total liabilities surged 36% to $2.1B, though the company maintained slightly higher cash reserves at $122.5M. Despite increased R&D spending of $416M and rising interest costs, the overall picture signals a company in serious financial distress with unsustainable cash burn and a balance sheet structure that raises going concern questions.

FINANCIAL STATEMENT CHANGES
Capital Expenditure
Cash Flow
+535.1%
$3.9M→$24.8M

Capital expenditure jumped 535.1% — major investment cycle underway; assess returns on deployment.

Stockholders Equity
Balance Sheet
-387.3%
-$135.4M→-$659.6M

Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.

Revenue
P&L
-87.4%
$106.4M→$13.4M

Revenue declined 87.4% — significant demand weakness or market share loss warrants investigation.

Total Liabilities
Balance Sheet
+35.6%
$1.5B→$2.1B

Liabilities grew 35.6% — significant increase in debt or obligations, assess impact on financial flexibility.

Net Income
P&L
-33.2%
-$589.5M→-$785.0M

Net income declined 33.2% — review whether driven by operations, interest costs, or non-recurring items.

Cash & Equivalents
Balance Sheet
+29.2%
$94.9M→$122.5M

Cash grew 29.2% — improving liquidity position supports investment and shareholder returns.

Operating Cash Flow
Cash Flow
-28.8%
-$395.9M→-$510.0M

Operating cash flow softened — monitor whether temporary working capital timing or structural deterioration.

R&D Expense
P&L
+22.6%
$339.4M→$416.0M

R&D investment increased 22.6% — signals commitment to future product development, though near-term margin impact.

Interest Expense
P&L
+20.9%
$37.7M→$45.6M

Interest costs rose 20.9% — monitor debt levels and coverage ratio in rising rate environment.

Current Assets
Balance Sheet
-17.2%
$1.1B→$917.0M

Current assets declined 17.2% — monitor working capital adequacy and short-term liquidity.

LANGUAGE CHANGES
NEW — 2026-02-26
PRIOR — 2025-02-27
ADDED
(A) (A) Excludes 43.8 million shares of common stock held by directors and executive officers, and any stockholders known to us whose ownership exceeded ten percent of our common stock outstanding as of June 30, 2025.
Bank National Association), as trustee, as supplemented by the First Supplemental Indenture, dated November 13, 2019, between Cytokinetics and U.S.
Bank National Association) 2026 Notes Cytokinetics 4% convertible senior notes due 2026 2027 Indenture Indenture, dated July 6, 2022, between Cytokinetics and U.S.
Bank Trust Company, as trustee 2027 Notes Cytokinetics 3.50% convertible senior notes due 2027 2031 Indenture Indenture, dated September 19, 2025, between Cytokinetics and U.S.
Food and Drug Administration Final Payment Amount As defined in Part II, Item 7 (Management s Discussion and Analysis of Financial Conditions and Results of Operations) of this Annual Report on Form 10-K Sources and Uses of Cash, Royalty Pharma Transactions FOREST-HCM Five-Year, Open-Label, Research Evaluation of Sustained Treatment with Aficamten in HCM Fundamental Change As defined in the 2026 Indenture, 2027 Indenture, or 2031 Indenture, as applicable GAAP Generally Accepted Accounting Principles in the U.S.
+7 more — sign up free →
REMOVED
(A) (A) Excludes 13.7 million shares of common stock held by directors and executive officers, and any stockholders whose ownership exceeds ten percent of the shares outstanding, at June 28, 2024.
Food and Drug Administration Final Payment Amount As defined in Part II, Item 7 (Management s Discussion and Analysis of Financial Conditions and Results of Operations) of this Annual Report on Form 10-K Sources and Uses of Cash, Royalty Pharma Transactions FOREST-HCM Five-Year, Open-Label, Research Evaluation of Sustained Treatment with Aficamten in HCM FSTA fast skeletal muscle troponin activator Fundamental Change As defined in the 2027 Indenture GAAP Generally Accepted Accounting Principles in the U.S.
1, dated January 7, 2022 RP Stock Purchase Agreement Common Stock Option and Purchase Agreement, dated May 22, 2024, by and between Cytokinetics and Royalty Pharma Investments 2019 ICAV RPDF Royalty Pharma Development Funding, LLC RPFT RPI Finance Trust RPI ICAV Royalty Pharma Investments 2019 ICAV RSU Restricted Stock Unit RTW ICAV RTW Investments ICAV for RTW Fund 1 RTW Investors RTW Master Fund, Ltd., RTW Innovation Master Fund, Ltd.
We intend that such statements be protected by the safe harbor created thereby.
Forward-looking statements involve risks and uncertainties and our actual results and the timing of events may differ significantly from the results discussed in the forward-looking statements.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →